X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ACTAVIS (US) - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ACTAVIS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ACTAVIS
Dec-14
AUROBINDO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs80920,152-   
Low Rs50412,292-   
Sales per share (Unadj.) Rs281.13,628.8-  
Earnings per share (Unadj.) Rs41.4-452.8-  
Cash flow per share (Unadj.) Rs50.9332.9-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.47,870.7-  
Shares outstanding (eoy) m585.88265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.5 52.3%   
Avg P/E ratio x15.9-35.8 -44.3%  
P/CF ratio (eoy) x12.948.7 26.5%  
Price / Book Value ratio x3.32.1 159.8%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6304,313,390 8.9%   
No. of employees `00017.321.6 80.2%   
Total wages/salary Rs m21,3080-   
Avg. sales/employee Rs Th9,500.744,670.8 21.3%   
Avg. wages/employee Rs Th1,229.40-   
Avg. net profit/employee Rs Th1,397.9-5,574.4 -25.1%   
INCOME DATA
Net Sales Rs m164,666964,890 17.1%  
Other income Rs m1,020-2,408 -42.3%   
Total revenues Rs m165,686962,482 17.2%   
Gross profit Rs m37,718123,954 30.4%  
Depreciation Rs m5,580208,934 2.7%   
Interest Rs m77730,434 2.6%   
Profit before tax Rs m32,380-117,823 -27.5%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,643 0.0%   
Tax Rs m8,183-6,057 -135.1%   
Profit after tax Rs m24,229-120,408 -20.1%  
Gross profit margin %22.912.8 178.3%  
Effective tax rate %25.35.1 491.5%   
Net profit margin %14.7-12.5 -117.9%  
BALANCE SHEET DATA
Current assets Rs m121,878508,373 24.0%   
Current liabilities Rs m86,806370,754 23.4%   
Net working cap to sales %21.314.3 149.3%  
Current ratio x1.41.4 102.4%  
Inventory Days Days13058 223.9%  
Debtors Days Days6866 103.1%  
Net fixed assets Rs m81,037117,823 68.8%   
Share capital Rs m5860-   
"Free" reserves Rs m116,2180-   
Net worth Rs m116,8042,092,811 5.6%   
Long term debt Rs m4,5121,096,674 0.4%   
Total assets Rs m211,0523,835,434 5.5%  
Interest coverage x42.7-2.9 -1,485.8%   
Debt to equity ratio x00.5 7.4%  
Sales to assets ratio x0.80.3 310.1%   
Return on assets %11.8-2.3 -505.1%  
Return on equity %20.7-5.8 -360.5%  
Return on capital %27.4-3.0 -908.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m46,0270-   
CASH FLOW
From Operations Rs m19,548165,690 11.8%  
From Investments Rs m-19,570-396,726 4.9%  
From Financial Activity Rs m8,642222,903 3.9%  
Net Cashflow Rs m8,922-8,133 -109.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.87 Rs / USD

Compare AUROBINDO PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: TORRENT PHARMA  PANACEA BIOTECH  JUBILANT LIFE SCIENCES  SHASUN PHARMA  WOCKHARDT LTD.  



Today's Market

Indian Indices Trade Strong; Capital Goods Stocks Lead Gains(12:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views On News

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Oct 3, 2018 | Updated on Oct 3, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 16, 2018 02:03 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS